Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,093 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Repeat Testing Clear all
Recruiting Phase 2 Interventional

Motixafortide for MRD Sensitization in AML

NCT07392970
View directory record Official record
Conditions
Acute Myeloid Leukemia, Measurable Residual Disease
Interventions
Motixafortide
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 21, 2026, 1:14 AM EDT
Recruiting Phase 4 Interventional

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

NCT05629494
View directory record Official record
Conditions
Prostate Cancer, Prostate Inflammation, PSA
Interventions
Ibuprofen 400 mg, TID, PSA test
Drug · Diagnostic Test
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Albany, New York • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 21, 2026, 1:14 AM EDT
Recruiting Not applicable Interventional

CHAMP Lung Cancer Screening Program

NCT07572773
View directory record Official record
Conditions
Lung Cancer, Early Lung Cancer Detection
Interventions
DELFI Diagnostics FirstLook Lung Cancer Screening Blood Test, Low-Does CT Scan
Diagnostic Test
Lead sponsor
Jill Kolesar
Other
Eligibility
50 Years to 77 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Iowa City, Iowa • Waterloo, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 21, 2026, 1:14 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03155620
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
1,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
168
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 21, 2026, 1:14 AM EDT
Completed No phase listed Observational

Genetic Markers in Patients With Colorectal Cancer

NCT00014079
View directory record Official record
Conditions
Colorectal Cancer
Interventions
DNA stability analysis, loss of heterozygosity analysis, microsatellite instability analysis
Genetic
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 21, 2026, 1:14 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

This Repeated Measures Parallel-group Investigation Will Examine the Influence of Short-term Melatonin Supplementation (5mg, 3 x Day for 72 Hours) on Cellular Responses, Functional Performance and Recovery Following an Acute Bout of Dynamic Resistance Exercise in Resistance Trained Men and Women

NCT06617351
View directory record Official record
Conditions
Cell Migration, Cell Invasion, Exercise Recovery
Interventions
Melatonin, Placebo
Dietary Supplement
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 21, 2026, 1:14 AM EDT
Completed Phase 2 Interventional

IRB-HSR # 14073 Investigation of Pelvic Girdle Dysfunction in the Low Back Pain Population

NCT02950129
View directory record Official record
Conditions
Back Pain
Interventions
SIJ pain diagnostic tests
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 64 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Oct 21, 2026, 1:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Examination of Glutamate and mGluR5 in Psychiatric Disorders

NCT02727972
View directory record Official record
Conditions
Major Depressive Disorder, Post-Traumatic Stress Disorder, Bipolar Disorder
Interventions
Cognitive Testing, MRI, PET
Behavioral · Other · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 21, 2026, 1:14 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

NCT06360575
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Crizotinib, Radiologic Examination
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 1:14 AM EDT
Recruiting Phase 3 Interventional

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

NCT06058377
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Interventions
Biospecimen Collection, Cyclophosphamide, Doxorubicin, Durvalumab, Genetic Testing, Mammography, Paclitaxel, Quality-of-Life Assessment
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3,680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
558
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 429 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 1:14 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Assessing the Effects of a Topically Applied Cream to Clitoral Blood Flow

NCT01085981
View directory record Official record
Conditions
Female Sexual Dysfunction
Interventions
arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%, Topical study cream, GRAS cream
Drug
Lead sponsor
East Suburban Ob Gyn
Other
Eligibility
25 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2010 · Synced Oct 21, 2026, 1:14 AM EDT
Not listed Not applicable Interventional

Screening for Liver Cancer With CT vs. Ultrasound in Patients With Advanced Liver Disease

NCT01350167
View directory record Official record
Conditions
Cirrhosis, End Stage Liver Disease, Hepatitis C
Interventions
Screening
Procedure
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 24, 2011 · Synced Oct 21, 2026, 1:14 AM EDT
Active, not recruiting Phase 2 Interventional

Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

NCT03284385
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Adavosertib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
29
States / cities
Orange, California • Sacramento, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 1:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

50 Human Subject Repeat Insult Patch Test

NCT04498676
View directory record Official record
Conditions
Erythema, Sensitisation
Interventions
CB-0002B
Other
Lead sponsor
CAGE Bio Inc.
Industry
Eligibility
21 Years to 67 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 21, 2026, 1:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Work Rate Adjustments During a High-intensity Interval Training on a Stationary Bike in a Hot and Temperate Environment

NCT05988606
View directory record Official record
Conditions
High-Intensity Interval Training, Heat
Interventions
15 minutes of high-intensity interval training, 43 minutes of high-intensity interval training, Hot environment, Temperate environment
Behavioral · Other
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
18 Years to 39 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 21, 2026, 1:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Skeletal Muscle Protein Synthesis: Traditional and Cluster Sets

NCT04028726
View directory record Official record
Conditions
Resistance Exercise
Interventions
Back-squat exercise
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
20 Years to 35 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 21, 2026, 1:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Validating Cardiac MRI Biomarkers and Genotype-Phenotype Correlations for DMD

NCT02834650
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Cardiac MRI with contrast, Cardiac MRI without contrast, Blood Test, Heart Rate, Pulmonary Function Test, Genetic Testing, Repeat MRI scan
Other
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 21 Years · Male only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
3
States / cities
Los Angeles, California • Orange, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 21, 2026, 1:14 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Achilles Pain Block

NCT03316378
View directory record Official record
Conditions
Achilles Tendon Pain
Interventions
Ropivacaine injection
Drug
Lead sponsor
Ruth Chimenti
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 21, 2026, 1:14 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

NCT03502733
View directory record Official record
Conditions
Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Bethesda, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 21, 2026, 1:14 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

NCT03816358
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Anetumab Ravtansine, Biopsy Procedure, Biospecimen Collection, Gemcitabine Hydrochloride, Ipilimumab, Nivolumab
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
44
States / cities
Birmingham, Alabama • Duarte, California • Irvine, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 21, 2026, 1:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

HeartPhone Cancer Survivors Trial 2019

NCT03953326
View directory record Official record
Conditions
Breast Cancer, Leukemia, Lymphoma
Interventions
HeartPhone app, Acetylcholine, Sodium Nitroprusside, L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester
Behavioral · Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 21, 2026, 1:14 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

NCT04439318
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Trametinib Dimethyl Sulfoxide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 21, 2026, 1:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

To Assess the Safety of a Sunscreen Product

NCT02803320
View directory record Official record
Conditions
Sunscreening Agents
Interventions
SPF 50 Y65 110 (BAY 987516)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 21, 2026, 1:14 AM EDT
Recruiting Phase 3 Interventional

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

NCT06661720
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
Interventions
Pembrolizumab, Tivozanib, Biospecimen Collection, MRI, Computed Tomography, Biopsy, Questionnaire Administration
Biological · Drug · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
425
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 339 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 21, 2026, 1:14 AM EDT